ScreenerHero

PROKProKidney Corp. Class A Ordinary Shares

NAS · US · Healthcare · Biotechnology · prokidney.com
1.610USD+8.78%Mkt Cap: 642.68M $P/E: —

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy wi…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap642.68M $
Enterprise Value1.23B $
Revenue (TTM)818.00K $
Gross Profit818.00K $
Net Income (TTM)-68.99M $
Revenue/Share0.0050 USD
Last Price1.610 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees231
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.42
PEG—
EV/EBITDA-7.19
EV/Revenue1497.56
P/S692.96
P/B-0.33
EPS (TTM)-0.53
EPS (Forward)-0.59
52W Range
1.30014% of range3.480
52W High3.480 USD
52W Low1.300 USD
Profitability
Gross Margin100.00%
Oper. Margin-32248.67%
EBITDA Margin0.00%
Profit Margin-7725.20%
ROE6.82%
ROA-20.56%
Growth
Revenue Growth-32.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-120.12M $
CapEx (TTM)15.20M $
FCF Margin-10249.98%
FCF Yield-13.05%
Net Debt-178.04M $
Net Debt/EBITDA1.05
Balance Sheet
Debt/Equity-0.00
Current Ratio8.36
Quick Ratio8.04
Book Value/Sh-4.2950 USD
Cash/Share0.8690 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)6.250 USD
Upside (mean)+288.2%
Target Range1.000 USD – 12.00 USD
$1.000+288.2% to mean$12.00
# Analysts6
Ownership
Shares Out.208.93M
Float159.74M
Insiders46.49%
Institutions26.28%
Short Interest
Short Ratio17.0d
Short % Float13.65%
Short % Out.10.09%
Shares Short20.71M
Short (prev mo.)19.43M
Technical
SMA 501.656 (-2.8%)
SMA 2001.994 (-19.2%)
Beta1.72
S&P 52W Chg18.16%
Avg Vol (30d)1.13M
Avg Vol (10d)1.47M
Technical Indicators
RSI (14)52.1
MACD-0.0503
MACD Signal-0.0505
MACD Hist.+0.0002
BB Upper1.734 USD
BB Middle1.545 USD
BB Lower1.356 USD
BB Width24.48%
ATR (14)0.1147 USD
Vol Ratio (20d)1.64x